Salute e Benessere

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12…

About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a…
PR Newswire
05/02/2025

GCCL Applauded by Frost & Sullivan for Ensuring Consistent, Reliable Clinical…

GCCL offers comprehensive in-house services that ensure rigorous quality control and deliver reliable clinical trial outcomes to support successful drug approvals. Unlike other global clinical lab organizations in the region that often outsource services (e.g., shipping samples for bio-analytical lab analysis to the United States, central lab samples to Singapore, and infectious materials to Biosafety Level 3 [BL3] facilities in other countries), GCCL operates as an "all-in-one lab for…
PR Newswire
05/02/2025

Interim report 2024/25 - Solid H1 performance driven by growth in both revenue…

ANNOUNCEMENT NO. 287 5 February 2025Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue for the first half of the year was up to DKK 251.5 million, a year-on-year increase of 26%. Growth was supported by a few large orders for the new XcytoMatic instruments in the wake of the customer validations initiated in the spring of 2024. Concurrently, we maintained our...
Nasdaq GlobeNewswire
05/02/2025

Avalere Health launches new commitment to make EVERY PATIENT POSSIBLE

Experience the full interactive Multichannel News Release here: https://www.multivu.com/avalere-health/9316551-en-avalere-health-make-every-patient-possible Experience the full interactive Multichannel News Release here:https://www.multivu.com/avalere-health/9316551-en-avalere-health-make-every-patient-possible The move comes in response to the evolving healthcare landscape. Despite unprecedented scientific and technological innovation, many people remain unable to benefit from the...
PR Newswire
05/02/2025

Doceree launches the first-ever unified admanager, built exclusively for…

Beyond streamlining ad operations, admanager, powered by Doceree empowers publishers to enhance the quality of their ad content, ensuring stronger engagement with healthcare professionals (HCPs) on their platforms. By leveraging advanced optimization tools and AI-driven insights, publishers can refine their messaging, improve relevancy, and create more impactful advertising experiences. Beyond streamlining ad operations,admanager, powered by Docereeempowers publishers to enhance the quality...
PR Newswire
05/02/2025

Peptide Synthesis Market to Hit USD 1.41 Billion by 2029 with 11.7% CAGR |…

Browse in-depth TOC on "Peptide Synthesis Market" Browse in-depth TOC on "Peptide Synthesis Market" 513 - Tables 55 - Figures 460 - Pages Based on offerings, the market is segmented into products and services. By-products market is further divided into consumables and instruments. Among these consumables dominated the peptide synthesis market. The consumables segment is further bifurcated into reagents and other consumables. The reagents market is further divided into...
PR Newswire
05/02/2025

ScreenPoint Medical: AI-Enhanced Mammography Screening Significantly Improves…

Published in The Lancet Digital Health, the Mammography Screening with Artificial Intelligence (MASAI) trial, conducted within the Swedish national screening program, demonstrates that Transpara®-assisted workflow increased cancer detection by 29% and resulted in a 44% reduction in the screen-reading workload for radiologists. The new results show an even greater increase in cancer detection than the interim results reported in 2023 (Lang et al, Lancet Oncology 24:8, p936-944) and provide more…
PR Newswire
05/02/2025

Sectra keeps #1 position in customer satisfaction--earns 8 Best in KLAS awards…

Sectra's 2025 Best in KLAS honors include: Sectra's 2025 Best in KLAS honors include: A US physician commented to KLAS Research inMarch 2024 : "With Sectra PACS, there was an immediate improvement in our return on investment and efficiency. We even improved things like the amount of time it takes to process the studies from the hardware vendors. There are so many little things. The vendor has a great dashboard to show how things have improved. Sectra PACS is a quantum leap above other…
PR Newswire
05/02/2025

Accumulus Synergy Powers Industry's First Digitally Generated Dossier to Nearly…

Leveraging the Accumulus platform, the digitally generated dossier created by Amgen using its proprietary AI and novel Structured Content and Data Management (SCDM) software is being reviewed by the Reliance Reference Country and all participating regulators at the same time. This means that every jurisdiction involved has real-time access to all regulatory information, from submission details to ongoing questions, answers, and updates, as it becomes available. This transparency not only has...
Nasdaq GlobeNewswire
05/02/2025

The Rainwater Charitable Foundation Unveils 2025 Rainwater Prize Winners…

The Rainwater Prize Program highlights groundbreaking scientific discoveries and aims to fill the critical gaps in neurodegenerative disease research, supporting and incentivizing researchers that are addressing unmet needs in primary tauopathies, and moving the needle forward for cutting-edge treatments. Dr. Blennow will be recognized for his development of novel cerebral spinal fluid (CSF) and blood-based tests for Alzheimer's disease-type tau pathology and his overall impact on the field of…
PR Newswire
05/02/2025

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

th -7 thFebruary 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressing through IND-enabling studies, with an IND submission anticipated during 2026.Presentation Details Title:Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and BFormat:Oral Presentation Presentation Number:OR10Date : 7 thFebruary 2025Session:SLAM About e-therapeutics plc e-therapeutics plc ("ETX") uniquely combines computation and...
Nasdaq GlobeNewswire
05/02/2025

Novo Nordisk files annual report with the SEC

Bagsværd, Denmark, 5 February 2025– Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2024. The reports are available at the SEC's website, www.sec.gov, as well as onnovonordisk.com. Shareholders may receive a hard copy of Novo Nordisk's completed audited financial statements free of charge upon request to...
Nasdaq GlobeNewswire
05/02/2025

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives…

- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function--Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025--Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025-- Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025-- Out-licensed greater-China anti-IGF-1R...
Nasdaq GlobeNewswire
05/02/2025

Hospital Filtration Market worth $3.19 billion by 2030- Exclusive Report by…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=251534296 Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=251534296 Inline filters is expected to be second largest segment by type during the forecast period. Inline filters are crucial elements of a filtration system in hospitals as they offer decontamination processes for the targeted pollutants from the air or water pipelines. These filters remove particles, bacteria,...
PR Newswire
05/02/2025

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT JANUARY 2025

Revenues were distributed as follows: Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &West Europe :Cyprus,France,Greece,Italy,Luxembourg,Malta,Netherlands,Slovenia,Spain,United Kingdom,Belgium,Ireland, Serbia,...
PR Newswire
05/02/2025

Embla Medical hf: Interim Report Q4 2024

Interim report Q4 2024 Interim report Q4 2024 COPENHAGEN, Denmark , Feb. 5, 2025 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "Sales in Q4 2024 amounted toUSD 225 million, where our organic sales growth was 5% for the quarter and local currency growth was 8%. The continued strong momentum we have seen throughout the year in our Prosthetics & Neuro Orthotics business continued to drive our growth, supported by good growth contribution across all our...
PR Newswire
05/02/2025

Liva Healthcare acquires Momenta, and secures funding from new and existing…

The purchase of Momenta comes as Liva has secured additional funding to accelerate its growth plans. The fundraising was led by a new investor, IBL Group, a Danish family-owned investment company, through its portfolio company Nupo, with participation from existing investors MIG, Santos, Maj Invest and other private investors. The purchase of Momenta comes as Liva has secured additional funding to accelerate its growth plans. The fundraising was led by a new investor, IBL Group, a Danish...
PR Newswire
05/02/2025

Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate…

"Receiving an IDE from the FDA is a landmark achievement for Newronika," said Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika. "It affirms the potential of our adaptive DBS system to fill an unmet need in the U.S. market, bringing personalized, real-time brain stimulation to patients who need it most. Our ultimate goal is to change the paradigm for managing neurological conditions worldwide, and this IDE moves us one step closer." "Receiving an IDE from the FDA is a…
PR Newswire
05/02/2025

Sobi publishes Q4 2024 report: A solid ending to a strong year

Full Year 2024 Full Year 2024 Outlook 2025 * The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant ®, Vonjo and Zynlonta ®, and royalty on Sanofi's sales of Altuviiio ® and Beyfortus. Investors, analysts, and the media are invited to a conference call on the same day at14:30 CET,13:30 GMT, and08:30 EST. The call will include a presentation of the results and a Q&A session. The presentation can be followed livehere...
PR Newswire
05/02/2025

Dawn Health and Novartis Launch Cora BC for Breast Cancer Support

Recognizing that every patient's journey is unique, Cora BC delivers curated, personalized content tailored to each individual patient's needs and experiences. From addressing common concerns to providing actionable advice, the app ensures patients have access to meaningful information when they need it most. Beyond education, Cora BC will help users stay organized by enabling diary entries and preparing for consultations, enabling more productive and informed discussions with healthcare…
PR Newswire
05/02/2025

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant…

Bagsværd, 5 February 2025-Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion. Operating profit was positively impacted by gross-to-net sales adjustments in the US and negatively impacted by...
Nasdaq GlobeNewswire
05/02/2025

Strong launch for Cresemba in Japan triggers first sales milestone payment from…

Allschwil, Switzerland, February 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba ®(isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.2 million. David Veitch, Chief Executive...
Nasdaq GlobeNewswire
05/02/2025

Valneva Receives Marketing Authorization in the UK for the World's First…

Saint Herblain (France), February 5, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world's first and only chikungunya vaccine, IXCHIQ ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and...
Nasdaq GlobeNewswire
05/02/2025

EyeYon Medical Expands into China with New Subsidiary

"We are incredibly excited to announce the establishment of our new subsidiary, a significant step in strengthening our commitment to the Chinese market," said Nahum Ferera, CEO. "This expansion allows us to directly address the unmet needs within the region and significantly intensify our growth trajectory." "We are incredibly excited to announce the establishment of our new subsidiary, a significant step in strengthening our commitment to the Chinese market," said…
PR Newswire
05/02/2025
Altri  Comunicati